Philips and Singapore General Hospital (SGH) to establish Digital and Computational Pathology Center of Excellence
October 23 2020 - 4:00AM
Philips and Singapore General Hospital (SGH) to establish Digital
and Computational Pathology Center of Excellence
October 23, 2020
- SGH aims to develop the first fully digitized histopathology
laboratory in ASEAN by expanding the use of Philips’ IntelliSite
Pathology Solution, potentially increasing the productivity of
existing staff by 7%
- Philips Singapore and SGH will optimize digital pathology use
to facilitate research in Artificial Intelligence (AI)
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG,
AEX: PHIA), a global leader in health technology, today announced a
collaboration with Singapore General Hospital (SGH) to establish
the Singapore General Hospital Digital and Computational Pathology
Center of Excellence. The SGH Center of Excellence aims to advance
pathology practice by implementing a fully digital histopathology
workflow and deploying Artificial Intelligence (AI) to increase
productivity and enhance patient care.
Located within SGH’s Division of Pathology, one of the largest
pathology laboratories in ASEAN, the Center of Excellence aims to
establish ASEAN’s first fully digitized histopathology laboratory
by expanding its digital pathology capabilities for primary
diagnosis, training, and R&D with the Philips IntelliSite
Pathology Solution. Both SGH and Philips will also work closely on
other diverse areas, including streamlining of the histopathology
laboratory’s digital workflow.
As in other parts of the world, the demand for cancer diagnosis
in Singapore is increasing while pathologists remain scarce. A
recent study, conducted by SGH and Philips, revealed that full
digitization of SGH’s histopathology laboratory will improve
efficiency. It has the potential to enable time savings in the
pathology workflow and allow the pathology department to increase
its capacity by another 7% whilst retaining the same number of
employees.
Through optimization of digital pathology at SGH, the hospital
will be able to further its research in AI. AI-based tools can aid
pathologists in diagnosing diseases such as cancer – the leading
cause of mortality in Singapore [1] – and empower them to face the
current challenges in pathology. The increasing number of cancer
cases, an aging population, and rapid advances in personalized
medicine have resulted in significant complexity of pathological
diagnostics, adding to the workload of pathologists. AI will allow
pathologists to focus more on challenging tasks and unusual cases
that require a higher degree of expertise and skills.
“As healthcare becomes more complex and demanding, digitization
has become a key enabler for the Hospital to provide better care
for our patients and to be more efficient,” said Prof. Kenneth
Kwek, Chief Executive Officer at SGH. “Digital pathology is an
example of that. Our partnership with companies such as Philips,
with its clinical and technical know-how, is important in helping
us achieve our goal.”
“Digital pathology enhances the quality and efficiency of a
histopathology laboratory,” said Diederik Zeven, General Manager,
Health Systems, Philips ASEAN Pacific. “We are committed to
partnering with leading healthcare institutions like Singapore
General Hospital to bring the latest in precision diagnosis and AI
capabilities to help them augment clinical quality, improving
patient outcomes and thereby reducing the cost of care.”
Philips IntelliSite Pathology Solution enables pathologists to
review and interpret digital images of surgical pathology slides
prepared from formalin-fixed paraffin-embedded (FFPE) tissue
samples. This technology replaces the need for traditional glass
slides to be viewed under a microscope, and facilitates referencing
and storage. Ultimately, digital images allow the application of
computer-aided image analysis with AI.
[1]
https://www.moh.gov.sg/resources-statistics/singapore-health-facts/principal-causes-of-death
For further information, please contact:
Mark GrovesPhilips Global Press OfficeTel.: +31 6 31 639
916E-mail: mark.groves@philips.com
Sheo S. RaiPhilips ASEAN PacificTel.: +65 978 426 56E-mail:
SheoShanker.Rai@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health
technology company focused on improving people's health and
well-being, and enabling better outcomes across the health
continuum – from healthy living and prevention, to diagnosis,
treatment and home care. Philips leverages advanced technology and
deep clinical and consumer insights to deliver integrated
solutions. Headquartered in the Netherlands, the company is a
leader in diagnostic imaging, image-guided therapy, patient
monitoring and health informatics, as well as in consumer health
and home care. Philips generated 2019 sales of EUR 19.5 billion and
employs approximately 81,000 employees with sales and services in
more than 100 countries. News about Philips can be found at
www.philips.com/newscenter.
About Singapore General Hospital Singapore General
Hospital, a member of Singapore Health Services, is the public
sector's flagship hospital. Established in 1821, SGH is Singapore's
largest acute tertiary hospital with 1,700 beds and national
referral center offering a comprehensive range of more than 40
clinical specialties on its campus. Every year, about 1 million
Singaporeans benefit from advanced medical care delivered by its
800 specialists. As an academic healthcare institution and the
bedrock of medical education, SGH plays a key role in nurturing
doctors, nurses and allied health professionals, and is committed
to innovative translational and clinical research in her continual
strive to provide the best care and outcomes to her patients.
www.sgh.com.sg
- Digital pathology at Singapore General Hospital
Koninklijke Philips NV (EU:PHIA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Koninklijke Philips NV (EU:PHIA)
Historical Stock Chart
From Sep 2023 to Sep 2024